OncoMatch/Clinical Trials/NCT06735495
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
Is NCT06735495 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies CD19&CD22 bispecific CAR-T cells for b-cell lymphoblastic leukemia/lymphoma.
Treatment: CD19&CD22 bispecific CAR-T cells — This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \& CD22 bispecific CAR-T cells in relapsed / refractory B cell hematological tumors while collecting pharmacokinetics and pharmacodynamics indicators of CAR-T cells.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 overexpression (positive by FCM or immunohistochemistry)
The results of FCM or immunohistochemical detection of tumor antigen (CD 19 / CD 22) were positive.
Required: CD22 overexpression (positive by FCM or immunohistochemistry)
The results of FCM or immunohistochemical detection of tumor antigen (CD 19 / CD 22) were positive.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: monoclonal antibody against CD20 — B-cell lymphoma
Subject must have received prior adequate treatment, including at least: a monoclonal antibody against CD 20
Must have received: anthracycline — B-cell lymphoma
combination chemotherapy containing an anthracycline drug agent
Lab requirements
Blood counts
hgb≥70g/l (transfusible)
Kidney function
creatinine ≤1.5xuln
Liver function
total bilirubin ≤1.5xuln; alt and ast≤2.5x uln
Cardiac function
left ventricular ejection fraction >50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06735495 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received monoclonal antibody against CD20 and anthracycline.
Does this trial require CD19?
Yes, CD19 overexpression is a required biomarker for enrollment.
Does this trial require CD22?
Yes, CD22 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 3 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify